Top

BMC Endocrine Disorders

Published in:

01-12-2021 | Obesity | Research

Investigation of the levels of circulating miR-29a, miR-122, sestrin 2 and inflammatory markers in obese children with/without type 2 diabetes: a case control study

Authors: Khalid M. Mohany, Osamah Al Rugaie, Osama Al-Wutayd, Abdullah Al-Nafeesah

Published in: BMC Endocrine Disorders | Issue 1/2021

Abstract

Aim

The present work investigated serum levels of miR-29a, miR-122 and sestrin2 in obese children with/without type-2-diabetes mellitus (T2DM), and their correlations with inflammatory, metabolic and anthropometric parameters.

Methods

The study included 298 children, divided into: G1 (control, n = 136), G2 (obese without diabetes, n = 90) and G3 (obese with T2DM, n = 72). Metabolic and anthropometric parameters, miR-29a, miR-122 relative expressions, and sestrin2, high sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) levels were measured by their specific methods. The data was processed and analyzed by SPSS V.26 using the corresponding tests. After testing the variables’ normality, Kruskal–Wallis one-way-ANOVA, Spearman correlations coefficient were used.

Results

Significant higher serum miR-29a, miR-122, IL-6, hsCRP and TNF-α and lower sestrin2 levels were found in G2 and G3 than G1 and in G3 than G2 (p= > 0.001 for all). Especially in G3, miR-29a and miR-122 levels correlated positively while sestrin2 levels correlated negatively with waist circumference and BMI percentiles, serum levels of LDL-cholesterol, triacylglycerol, total cholesterol, HbA1c%, glucose, insulin, c-peptide, homeostatic model assessment-insulin resistance (HOMA-IR), IL-6, hsCRP and TNF-α.

Conclusion

The change in the serum miR-29a, miR-122 and sestrin2 levels in obese children with/without T2DM may suggest a possible role of these biomarkers in the pathogenesis of childhood obesity and their accompanied complications e.g. inflammations and T2DM. Also, further studies are required to test drugs that antagonize the action miR-29a and miR-122 or upregulate sestrin2 in the management of these cases.

Available only for authorised users

NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627–42. https://doi.org/10.1016/S0140-6736(17)32129-3.CrossRef

Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–98. https://doi.org/10.1038/s41574-019-0176-8.CrossRefPubMed

World Health Organization (WHO). Country Cooperation Strategy for WHO and Saudi Arabia 2012–2016. 2013. Retrieved from http://www.who.int/countryfocus/cooperation_strategy/ccs_sau_en.pdf.

Al Dhaifallah A, Mwanri L, Aljoudi A. Childhood obesity in Saudi Arabia: opportunities and challenge. Saudi Journal of obesity. 2015;3(1):2–7.CrossRef

Cui X, You L, Zhu L, Wang X, Zhou Y, Wen J, et al. Change in circulating miR profile of obese children indicates future risk of adult diabetes. Metab Clin Exp. 2018;78:95–105. https://doi.org/10.1016/j.metabol.2017.09.006.CrossRefPubMed

Weintrob N, Stern E, Klipper-Aurbach Y, Phillip M, Gat-Yablonski G. Childhood obesity complicating the differential diagnosis of maturity-onset diabetes of the young and type 2 diabetes. Pediatr Diabetes. 2008;9(1):60–4. https://doi.org/10.1111/j.1399-5448.2007.00259.x.CrossRefPubMed

Ellulu MS, Patimah I, Khaza'ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13(4):851–63. https://doi.org/10.5114/aoms.2016.58928.CrossRefPubMed

Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98–107. https://doi.org/10.1038/nri2925.CrossRefPubMed

Wolowczuk I. Obesity–an inflammatory state. Acta Vet Scand. 2015;57(1):K5. https://doi.org/10.1186/1751-0147-57-S1-K5.CrossRefPubMedCentral

10.

Carolan E, Hogan AE, Corrigan M, Gaotswe G, O'Connell J, Foley N, et al. The impact of childhood obesity on inflammation, innate immune cell frequency, and metabolic miR expression. J Clin Endocrinol Metab. 2014;99(3):E474–8. https://doi.org/10.1210/jc.2013-3529.CrossRefPubMed

11.

Iacomino G, Siani A. Role of miRs in obesity and obesity-related diseases. Genes Nutr. 2017;12(1):23. https://doi.org/10.1186/s12263-017-0577-z.CrossRefPubMedPubMedCentral

12.

Mohany KM, Al Rugaie O, Al-wutayd O, Al-Nafeesah A, Saleem TH. Association between circulating miRs 486, 146b and 15b and serum betatrophin levels in obese; type 2 diabetic and non-diabetic children. BMC Endocr Disord. 2020;20(1):145.CrossRefPubMedPubMedCentral

13.

Feng J, Xing W, Xie L. Regulatory roles of MiRs in diabetes. Int J Mol Sci. 2016;17(10):1729. https://doi.org/10.3390/ijms17101729.CrossRefPubMedCentral

14.

Tang B, Li X, Ren Y, Wang J, Xu D, Hang Y, et al. MiR-29a regulates lipopolysaccharide (LPS)-induced inflammatory responses in murine macrophages through the Akt1/ NF-κB pathway. Exp Cell Res. 2017;360(2):74–80. https://doi.org/10.1016/j.yexcr.2017.08.013.CrossRefPubMed

15.

Zhong H, Ma M, Liang T, Guo L. Role of MiRs in obesity-induced metabolic disorder and immune response. J Immunol Res. 2018;Article ID 2835761:8 https://doi.org/10.1155/2018/2835761.

16.

Shah R, Murthy V, Pacold M, Danielson K, Tanriverdi K, Larson MG, et al. Extracellular RNAs are associated with insulin resistance and metabolic phenotypes. Diabetes Care. 2017;40(4):546–53. https://doi.org/10.2337/dc16-1354.CrossRefPubMedPubMedCentral

17.

Sendi H, Mead I, Wan M, Mehrab-Mohseni M, Koch K, Atala A, et al. miR-122 inhibition in a human liver organoid model leads to liver inflammation, necrosis, steatofibrosis and dysregulated insulin signaling. PLoS One. 2018;13(7):e0200847.CrossRefPubMedPubMedCentral

18.

Lee JH, Budanov AV, Talukdar S, Park EJ, Park HL, Park HW, et al. Maintenance of metabolic homeostasis by Sestrin2 and Sestrin3. Cell Metab. 2012;16(3):311–21. https://doi.org/10.1016/j.cmet.2012.08.004.CrossRefPubMedPubMedCentral

19.

Nourbakhsh M, Sharifi R, Ghorbanhosseini SS, Javad A, Ahmadpour F, Razzaghy Azar M, et al. Evaluation of plasma TRB3 and Sestrin 2 levels in obese and Normal-weight children. Child Obes. 2017;13(5):409–14. https://doi.org/10.1089/chi.2017.0082.CrossRefPubMed

20.

Chung HS, Hwang HJ, Hwang SY, Kim NH, Seo JA, Kim SG, et al. Association of serum Sestrin 2 level with metabolic risk factors in newly diagnosed drug-naïve type 2 diabetes. Diabetes Res Clin Pract. 2018;144:34–41. https://doi.org/10.1016/j.diabres.2018.07.024.CrossRefPubMed

21.

Temneanu OR, Trandafir LM, Purcarea MR. Type 2 diabetes mellitus in children and adolescents: a relatively new clinical problem within pediatric practice. J Med Life. 2016;9(3):235–9.PubMedPubMedCentral

22.

Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of LDL-C in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18:449–502.CrossRef

23.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9. https://doi.org/10.1007/BF00280883.CrossRefPubMed

24.

Lim LP, Glasner ME, Yekta S, Burge CB, Bartel DP. Vertebrate microRNA genes. Science. 2003;7;299(5612):1540.

25.

Reinehr T. Inflammatory markers in children and adolescents with type 2 diabetes mellitus. Clin Chim Acta. 2019;496:100–7. https://doi.org/10.1016/j.cca.2019.07.006.CrossRefPubMed

26.

Smitka K, Maresova D. Adipose tissue as an endocrine organ: an update on pro-inflammatory and anti-inflammatory microenvironment. Prague Med Rep. 2015;116(2):87–111. https://doi.org/10.14712/23362936.2015.49.CrossRefPubMed

27.

Marques-Rocha JL, Samblas M, Milagro FI, Bressan J, Martínez JA, Marti A. Noncoding RNAs, cytokines, and inflammation-related diseases. FASEB J. 2015;29(9):3595–611. https://doi.org/10.1096/fj.14-260323.CrossRefPubMed

28.

Zhou Y, Gu P, Shi W, Li J, Hao Q, Cao X, et al. MiR-29a induces insulin resistance by targeting PPARδ in skeletal muscle cells. Int J Mol Med. 2016;37(4):931–8. https://doi.org/10.3892/ijmm.2016.2499.CrossRefPubMedPubMedCentral

29.

Tahamtan A, Teymoori-Rad M, Nakstad B, Salimi V. Anti-inflammatory MiRs and their potential for inflammatory diseases treatment. Front Immunol. 2018;9:1377. https://doi.org/10.3389/fimmu.2018.01377.CrossRefPubMedPubMedCentral

30.

Pandey AK, Verma G, Vig S, Srivastava S, Srivastava AK, Datta M. miR-29a levels are elevated in the db/db mice liver and its overexpression leads to attenuation of insulin action on PEPCK gene expression in HepG2 cells. Mol Cell Endocrinol. 2011;332(1–2):125–33. https://doi.org/10.1016/j.mce.2010.10.004.CrossRefPubMed

31.

Yang WM, Jeong HJ, Park SY, Lee W. Induction of miR-29a by saturated fatty acids impairs insulin signaling and glucose uptake through translational repression of IRS-1 in myocytes. FEBS Lett. 2014;588(13):2170–6. https://doi.org/10.1016/j.febslet.2014.05.011.CrossRefPubMed

32.

Ortega FJ, Mercader JM, Moreno-Navarrete JM, Rovira O, Guerra E, Esteve E, et al. Profling of circulating miRs reveals common miRs linked to type 2 diabetes that change with insulin sensitization. Diabetes Care. 2014;37(5):1375–83. https://doi.org/10.2337/dc13-1847.CrossRefPubMed

33.

Fernández-Hernando C, Ramírez CM, Goedeke L, Suárez Y. MiRs in metabolic disease. Arterioscler Thromb Vasc Biol. 2013;33(2):178–85. https://doi.org/10.1161/ATVBAHA.112.300144.CrossRefPubMedPubMedCentral

34.

De Rosa S, Arcidiacono B, Chiefari E, Brunetti A, Indolfi C, Foti DP. Type 2 diabetes mellitus and cardiovascular disease: genetic and epigenetic links. Front Endocrinol (Lausanne). 2018;9:2. https://doi.org/10.3389/fendo.2018.00002.CrossRef

35.

Yang YM, Seo SY, Kim TH, Kim SG. Decrease of miR-122 causes hepatic insulin resistance by inducing protein tyrosine phosphatase 1B, which is reversed by licorice flavonoid. Hepatology. 2012;56(6):2209–20. https://doi.org/10.1002/hep.25912.CrossRefPubMed

36.

Jones A, Danielson KM, Benton MC, Ziegler O, Shah R, Stubbs RS, et al. miRNA signatures of insulin resistance in obesity. Obesity. 2017;25(10):1734–44. https://doi.org/10.1002/oby.21950.CrossRefPubMed

37.

Wang R, Hong J, Cao Y, Shi J, Gu W, Ning G, et al. Elevated circulating miR-122 is associated with obesity and insulin resistance in young adults. Eur J Endocrinol. 2015;172(3):291–300. https://doi.org/10.1530/EJE-14-0867.CrossRefPubMed

38.

Ortega FJ, Moreno-Navarrete JM, Pardo G, Sabater M, Hummel M, Ferrer A, et al. MiRNA Expression Profile of Human Subcutaneous Adipose and during Adipocyte Differentiation. PLoS One. 2010;5(2):e9022.CrossRefPubMedPubMedCentral

39.

Prats-Puig A, Ortega FJ, Mercader JM, Moreno-Navarrete JM, Moreno M, Bonet N, et al. Changes in circulating miRs are associated with childhood obesity. J Clin Endocrinol Metab. 2013;98(10):E1655–60. https://doi.org/10.1210/jc.2013-1496.CrossRefPubMed

40.

de Candia P, Spinetti G, Specchia C, Sangalli E, La Sala L, Uccellatore A, et al. A unique plasma miR profile defines type 2 diabetes progression. PLoS One. 2017;12(12):e0188980. https://doi.org/10.1371/journal.pone.0188980.CrossRefPubMedPubMedCentral

41.

Willeit P, Skroblin P, Moschen AR, Yin X, Kaudewitz D, Zampetaki A, et al. Circulating miR-122 is associated with the risk of new-onset metabolic syndrome and type 2 diabetes. Diabetes. 2017;66(2):347–57. https://doi.org/10.2337/db16-0731.CrossRefPubMed

42.

Zhang HN, Xu QQ, Thakur A, Alfred MO, Chakraborty M, Ghosh A, et al. Endothelial dysfunction in diabetes and hypertension: role of miRs and long non-coding RNAs. Life Sci. 2018;213:258–68. https://doi.org/10.1016/j.lfs.2018.10.028.CrossRefPubMed

43.

Song JJ, Yang M, Liu Y, Song JW, Wang J, Chi HJ, et al. MiR-122 aggravates angiotensin II-mediated apoptosis and autophagy imbalance in rat aortic adventitial fibroblasts via the modulation of SIRT6-elabela-ACE2 signaling. Eur J Pharmacol. 2020;883:173374. https://doi.org/10.1016/j.ejphar.2020.173374.CrossRefPubMedPubMedCentral

44.

Zhao Z, Zhong L, Li P, He K, Qiu C, Zhao L, et al. Cholesterol impairs hepatocyte lysosomal function causing M1 polarization of macrophages via exosomal miR-122-5p. Exp Cell Res. 2020;387(1):111738. https://doi.org/10.1016/j.yexcr.2019.111738.CrossRefPubMed

45.

Wang Y, Liang H, Jin F, Yan X, Xu G, Hu H, et al. Injured liver-released miRNA-122 elicits acute pulmonary inflammation via activating alveolar macrophage TLR7 signaling pathway. Proc Natl Acad Sci U S A. 2019;116(13):6162–71. https://doi.org/10.1073/pnas.1814139116.CrossRefPubMedPubMedCentral

46.

Lee JH, Budanov AV, Karin M. Sestrins orchestrate cellular metabolism to attenuate aging. Cell Metab. 2013;18(6):792–801. https://doi.org/10.1016/j.cmet.2013.08.018.CrossRefPubMed

47.

Sun W, Wang Y, Zheng Y, Quan N. The emerging role of Sestrin 2 in cell metabolism, and cardiovascular and age-related diseases. Aging Dis. 2020;11(1):154–63. https://doi.org/10.14336/AD.2019.0320.CrossRefPubMedPubMedCentral

48.

Ro SH, Xue X, Ramakrishnan SK, Cho CK, Namkoong S, Jang I, et al. Tumor suppressive role of sestrin2 during colitis and colon carcinogenesis. eLife. 2016;5:e12204.CrossRefPubMedPubMedCentral

49.

Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471–84. https://doi.org/10.1016/j.cell.2006.01.016.CrossRefPubMed

50.

Mohany KM and Al Rugaie. Association of serum sestrin 2 and betatrophin with serumneutrophil gelatinase associated lipocalin levels in type 2 diabetic patients with diabetic nephropathy. J Diabetes Metab Disord. 2020; 6;19(1):249–256.

51.

Sundararajan S, Jayachandran I, Subramanian SC, Anjana RM, Balasubramanyam M, Mohan V, et al. Decreased Sestrin levels in patients with type 2 diabetes and dyslipidemia and their association with the severity of atherogenic index. J Endocrinol Investig. 2020. https://doi.org/10.1007/s40618-020-01429-9;44(7):1395–405.CrossRef

52.

Chai D, Wang G, Zhou Z, Yang H, Yu Z. Insulin Increases Sestrin 2 Content by Reducing Its Degradation through the PI 3 K/mTOR Signaling Pathway. Int J Endocrinol. 2015;2015:505849. https://doi.org/10.1155/2015/505849 Epub 2015 Feb 22. PMID: 25792980; PMCID: PMC4352509.CrossRefPubMedPubMedCentral

Title: Investigation of the levels of circulating miR-29a, miR-122, sestrin 2 and inflammatory markers in obese children with/without type 2 diabetes: a case control study
Authors: Khalid M. Mohany
Osamah Al Rugaie
Osama Al-Wutayd
Abdullah Al-Nafeesah
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Obesity
Obesity
Insulins
Insulins
Published in: BMC Endocrine Disorders / Issue 1/2021
Electronic ISSN: 1472-6823
DOI: https://doi.org/10.1186/s12902-021-00829-z

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Aim

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

The role of FDX1 in granulosa cell of Polycystic ovary syndrome (PCOS)

Providing lifestyle advice to women with PCOS: an overview of practical issues affecting success

The epidemiology of primary and secondary adrenal malignancies and associated adrenal insufficiency in hospitalised patients: an analysis of hospital admission data, NSW, Australia

Clinical risk score for central precocious puberty among girls with precocious pubertal development: a cross sectional study

Using real-world data to estimate the changing trends in the prevalence and incidence of type 2 diabetes mellitus in Xiamen of China from 2014 to 2019

The association between subclinical hypothyroidism and TPOAb positivity with infertility in a population-based study: Tehran thyroid study (TTS)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage